These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors. Yeo SP; Kua L; Tan JW; Lim JK; Wong FH; Santos MD; Poh CM; Goh AX; Koh XY; Zhou X; Rajarethinam R; Chen Q; Her Z; Horak ID; Low L; Tan KW Cancer Res Commun; 2024 Jun; 4(6):1410-1429. PubMed ID: 38717140 [TBL] [Abstract][Full Text] [Related]
7. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008 [No Abstract] [Full Text] [Related]
8. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445 [TBL] [Abstract][Full Text] [Related]
9. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315 [TBL] [Abstract][Full Text] [Related]
10. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616 [TBL] [Abstract][Full Text] [Related]
11. Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma. Lake JA; Woods E; Hoffmeyer E; Schaller KL; Cruz-Cruz J; Fernandez J; Tufa D; Kooiman B; Hall SC; Jones D; Hayashi M; Verneris MR J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39043604 [TBL] [Abstract][Full Text] [Related]
12. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models. Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297 [TBL] [Abstract][Full Text] [Related]
13. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model. Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H Front Immunol; 2021; 12():628906. PubMed ID: 33777013 [TBL] [Abstract][Full Text] [Related]
14. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527 [TBL] [Abstract][Full Text] [Related]
15. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914 [TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Qu J; Mei Q; Chen L; Zhou J Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047 [TBL] [Abstract][Full Text] [Related]
17. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma. Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589 [TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice. Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955 [TBL] [Abstract][Full Text] [Related]
19. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980 [TBL] [Abstract][Full Text] [Related]
20. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Theruvath J; Sotillo E; Mount CW; Graef CM; Delaidelli A; Heitzeneder S; Labanieh L; Dhingra S; Leruste A; Majzner RG; Xu P; Mueller S; Yecies DW; Finetti MA; Williamson D; Johann PD; Kool M; Pfister S; Hasselblatt M; Frühwald MC; Delattre O; Surdez D; Bourdeaut F; Puget S; Zaidi S; Mitra SS; Cheshier S; Sorensen PH; Monje M; Mackall CL Nat Med; 2020 May; 26(5):712-719. PubMed ID: 32341579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]